Mount Vernon Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.06M Hold
920
– – 0.71% 32
2026
Q2
$1.1M Buy
920
+30
+3% +$30.7K 0.72% 33
2026
Q1
$819K Hold
890
– – 0.58% 35
2025
Q4
$956K Hold
890
– – 0.64% 32
2025
Q3
$679K Sell
890
-50
-5% -$37.2K 0.47% 35
2025
Q2
$733K Hold
940
– – 0.53% 34
2025
Q1
$776K Hold
940
– – 0.63% 33
2024
Q4
$726K Hold
940
– – 0.57% 34
2024
Q3
$833K Buy
940
+400
+74% +$360K 0.66% 34
2024
Q2
$489K Sell
540
-550
-50% -$440K 0.43% 39
2024
Q1
$848K Sell
1,090
-30
-3% -$21.4K 0.72% 34
2023
Q4
$653K Hold
1,120
– – 0.64% 34
2023
Q3
$602K Sell
1,120
-10
-0.9% -$5.15K 0.67% 34
2023
Q2
$530K Sell
1,130
-24
-2% -$10.1K 0.56% 35
2023
Q1
$396K Hold
1,154
– – 0.47% 36
2022
Q4
$422K Hold
1,154
– – 0.54% 37
2022
Q3
$373K Hold
1,154
– – 0.49% 38
2022
Q2
$374K Hold
1,154
– – 0.46% 39
2022
Q1
$330K Hold
1,154
– – 0.32% 44
2021
Q4
$319K Hold
1,154
– – 0.28% 44
2021
Q3
$267K Sell
1,154
-170
-13% -$42K 0.24% 46
2021
Q2
$304K Hold
1,324
– – 0.28% 45
2021
Q1
$247K Hold
1,324
– – 0.24% 46
2020
Q4
$224K Buy
+1,324
New +$198K 0.24% 48
2020
Q3
– Sell
-1,324
Closed -$217K – 55
2020
Q2
$217K Sell
1,324
-500
-27% -$76.8K 0.28% 44
2020
Q1
$253K Hold
1,824
– – 0.42% 39
2019
Q4
$240K Hold
1,824
– – 0.33% 43
2019
Q3
$204K Hold
1,824
– – 0.31% 45
2019
Q2
$202K Hold
1,824
– – 0.3% 46
2019
Q1
$237K Hold
1,824
– – 0.36% 47
2018
Q4
$211K Buy
+1,824
New +$204K 0.37% 45

Other funds holding LLY

Mount Vernon Associates's LLY Position: Q3 2026 in Review

Mount Vernon Associates held its Eli Lilly (LLY) position steady in Q3 2026 at 920 shares worth $1.06M. The position accounts for 0.71% of the portfolio, ranked #32.

Mount Vernon Associates first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.1M in Q2 2026. 4,628 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Mount Vernon Associates held 920 shares of Eli Lilly worth $1.06M as of Q3 2026.
  • Mount Vernon Associates left its Eli Lilly share count unchanged in Q3 2026.
  • Eli Lilly made up 0.71% of Mount Vernon Associates's portfolio in Q3 2026, its #32 holding.
  • Mount Vernon Associates first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
  • Mount Vernon Associates's Eli Lilly position peaked at $1.1M in Q2 2026.
  • 4,628 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Mount Vernon Associates's 13F filing for Q3 2026, filed 26 Oct 2026.